Acorda Therapeutics. has filed a patent for a dry powder lung surfactant formulation for inhalation delivery. The formulation includes DPPC, NaCl, excipients like leucine, and surfactant proteins SP-A, SP-B, SP-C, or SP-D. This innovation aims to improve pulmonary drug delivery. GlobalData’s report on Acorda Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Acorda Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Acorda Therapeutics's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Dry powder lung surfactant formulation for inhalation delivery
See Also:
The patent application (Publication Number: US20240016823A1) discloses a novel respirable, dry powder particle surfactant formulation designed for pulmonary delivery. The formulation includes key components such as DPPC, NaCl, and an excipient like leucine or mannitol, along with a surfactant protein like SP-A or SP-D. The dry powder particles are carefully composed to ensure a total weight percent of 100, making it suitable for effective pulmonary delivery.
Moreover, the patent application outlines a method for treating patients in need of lung surfactant therapy by administering the formulated dry powder particles through pulmonary delivery. The therapy is targeted towards patients suffering from conditions like lung surfactant deficiency due to respiratory distress syndrome, asthma, pneumonia, or other respiratory ailments. The method covers a wide range of patients, including adult humans and pediatric individuals across various age groups, emphasizing the versatility and potential impact of the disclosed formulation in addressing lung-related health issues.
To know more about GlobalData’s detailed insights on Acorda Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
